Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine in bladder cancer.

Fadi El Karak1, Aude Flechon

  • 1Centre Léon Bérard, Department of Medical Oncology, 28 Rue Laennec, 69008, Lyon, France. colodine@hotmail.com

Expert Opinion on Pharmacotherapy
|November 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.

European urology oncology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026
Same author

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.

Frontiers in oncology·2026
Same author

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Gemcitabine, a DNA synthesis inhibitor, shows significant activity in various stages of urothelial bladder cancer. Despite potential myelosuppression, it offers a favorable toxicity profile for patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Gemcitabine is a deoxycytidine analogue that inhibits DNA synthesis.
  • It has a generally favorable toxicity profile, with myelosuppression as the most serious concern.
  • Gemcitabine has been evaluated in urothelial bladder cancer across different disease stages.

Purpose of the Study:

  • To review studies on gemcitabine's efficacy in bladder cancer.
  • To highlight its usefulness in various treatment settings.

Main Methods:

  • Review of clinical studies involving gemcitabine in urothelial bladder cancer.
  • Analysis of efficacy and toxicity data from different treatment scenarios.

Main Results:

  • Intravesical gemcitabine demonstrates significant activity in Bacillus Calmette-Guérin (BCG)-resistant and intolerant superficial bladder cancer.

Related Experiment Videos

  • The combination of gemcitabine and cisplatin (GC) is a feasible adjuvant regimen.
  • GC is a standard first-line option for locally advanced and metastatic bladder cancer.
  • Gemcitabine is a viable option for unfit patients, alone or with carboplatin or taxanes.

    • Conclusions:

    • Gemcitabine is a versatile chemotherapeutic agent for urothelial bladder cancer.
    • Its efficacy is demonstrated in both early-stage and advanced disease settings.
    • Gemcitabine offers a valuable treatment option, particularly for specific patient groups.